Provenge likely to be approved in Europe later this year

The European Medicines Agency’s Committee for Medicinal Products for Human Use today recommended that marketing authorization be approved for sipuleucel-T (Provenge) in the European Union. A final decision by the European Commission is likely later this year.

According to a media release issued by Dendreon, the committee recommended that Provenge be cleared to treat men with asymptomatic or minimally symptomatic, metastatic (non-visceral), castrate-resistant prostate cancer for whom chemotherapy is not yet clinically indicated.

Of course an approval in Europe does not necessarily mean that a product becomes available to patients through the national health systems of individual nations, so there is a way to go yet before we will know just how widely sipuleucel-T becomes available in Europe.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: